Drug intelligence / Profile preview

OP-I-03

Development stage: Preclinical
Lead developer: Omikron
Modality: Small Molecules
Administration: Intravenous

Overview

OP-I-03 is an investigational injectable solution being developed by Omikron Italia for the treatment of vascular conditions. As of early 2024, the product is listed in the company's research and development pipeline with an expected launch date of 2028. Specific details regarding its molecular target, mechanism of action, and precise clinical indication within the vascular therapeutic area have not been publicly disclosed by the developer. It is categorized as a parenteral product under development alongside other candidates in the OP-I series.

Beyond the preview

Go deeper on OP-I-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP-I-03.

Explore the full profile